Table 3.
Clinicopathological characteristics of gastric cancer (n = 62) | Expression of CD 44 protein (%) | OR (95% CI) | p value | |
---|---|---|---|---|
Negative | Positive | |||
Location of tumor (%) | ||||
(i) Upper | 5.12 | 10.25 | 0.62 (0.48–0.87) | 0.724 |
(ii) Middle | 10.25 | 15.38 | 0.87 (0.64–1.09) | 0.953 |
(iii) Lower | 7.69 | 58.84 | 4.69 (2.01–6.48) | 0.014∗ |
Tumor size (%) | ||||
(i) ≥70 mm | 7.69 | 48.71 | 5.74 (3.18–8.29) | 0.019∗ |
(ii) ≤70 mm | 20.51 | 23.07 | 0.54 (0.42–0.76) | 0.834 |
Histologic type (%) | ||||
(i) Differentiated | 23.07 | 17.94 | 0.73 (0.59–0.92) | 0.524 |
(ii) Undifferentiated | 5.12 | 53.84 | 8.29 (6.38–12.19) | 0.014∗ |
Lymphatic invasion (%) | ||||
(i) Absent | 41.02 | 7.69 | 4.21 (1.29–7.74) | 0.028∗ |
(ii) Present | 12.82 | 38.46 | 3.39 (1.69–5.58) | 0.032∗ |
Vascular invasion (%) | ||||
(i) Absent | 30.76 | 20.51 | 0.79 (0.62–1.38) | 0.497 |
(ii) Present | 25.64 | 23.07 | 0.59 (0.42–1.18) | 0.326 |
Pathological T stage (%) | ||||
(i) T1-T2 | 30.76 | 28.20 | 0.82 (0.63–1.13) | 0.284 |
(ii) T3-T4 | 20.51 | 46.15 | 2.19 (1.02–6.29) | 0.039∗ |
Pathological TNM stage (%) | ||||
(i) I | 7.69 | 5.12 | 0.92 (0.76–1.32) | 0.562 |
(ii) II | 17.97 | 12.82 | 0.72 (0.51–1.15) | 0.481 |
(iii) III | 5.12 | 28.02 | 4.49 (1.12–7.84) | 0.010∗ |
(iv) IV | 2.56 | 20.51 | 3.32 (1.45–5.890) | 0.029∗ |
Residual tumor [n = 29] (%) | ||||
(i) No | 58.97 | 15.38 | 2.89 (1.07–4.69) | 0.039∗ |
(ii) Microscopic | 2.56 | 10.25 | 1.54 (1.01–4.43) | 0.041∗ |
(iii) Gross (unresectable) | 5.12 | 7.69 | 0.74 (0.53–0.91) | 0.624 |
CEA (%) | ||||
(i) <5.0 (ng/ml) | 28.02 | 33.33 | 0.69 (0.58–1.42) | 0.573 |
(ii) ≥5.0 (ng/ml) | 17.94 | 20.51 | 0.98 (0.75–1.54) | 0.782 |
5 years survival (available n = 149) (%) |
55.03 | 14.76 | 2.83 (1.98–5.62) | 0.028∗ |
Univariate Cox regression model analysis used to analyze the data. OR, odds ratio; CI, confidence interval. ∗Significance is set at p < 0.05.